OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Sells $437,040.00 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 18,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $24.28, for a total value of $437,040.00. Following the completion of the transaction, the insider directly owned 6,863,464 shares of the company’s stock, valued at $166,644,905.92. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The shares were sold at an average price of $24.74, for a total value of $403,262.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $25.75, for a total value of $103,000.00.

OrthoPediatrics Price Performance

NASDAQ KIDS traded down $0.47 during trading hours on Wednesday, hitting $24.03. The company had a trading volume of 169,608 shares, compared to its average volume of 171,545. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The firm has a 50 day simple moving average of $21.11 and a 200 day simple moving average of $18.53. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. The firm has a market capitalization of $627.42 million, a price-to-earnings ratio of -14.30 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The firm had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. Equities research analysts expect that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On OrthoPediatrics

A number of institutional investors and hedge funds have recently bought and sold shares of KIDS. Russell Investments Group Ltd. lifted its position in OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares during the last quarter. Legal & General Group Plc bought a new position in shares of OrthoPediatrics in the 2nd quarter worth $34,000. Northwestern Mutual Wealth Management Co. raised its position in shares of OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after buying an additional 2,561 shares in the last quarter. Caption Management LLC purchased a new stake in shares of OrthoPediatrics during the 3rd quarter valued at $54,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Piper Sandler reiterated an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. BTIG Research boosted their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Finally, Truist Financial set a $22.00 price objective on OrthoPediatrics in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.